<DOC>
	<DOCNO>NCT00070109</DOCNO>
	<brief_summary>This phase II trial study well trabectedin work treat young patient recurrent refractory soft tissue sarcoma Ewing 's family tumor . Drugs use chemotherapy trabectedin use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Trabectedin Treating Young Patients With Recurrent Refractory Soft Tissue Sarcoma Ewing 's Family Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate pediatric patient recurrent refractory soft tissue sarcomas Ewing 's sarcoma family tumor treat ecteinascidin 743 ( trabectedin ) . II . Determine toxicity drug patient . III . Determine pharmacokinetics drug patient . OUTLINE : Patients receive trabectedin IV 3 hour day 1 . Treatment repeat every 21days 26 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Patients must great equal 12 month age time study entry 21 year age initially diagnose malignancy treat protocol Histologically confirm recurrent refractory sarcoma tumor , include follow : Rhabdomyosarcoma Nonrhabdomyosarcomatous soft tissue sarcoma Ewing 's sarcoma Measurable disease image study Lesions assessable radionuclide scan consider measurable If measurable lesion previously irradiate , lesion must show evidence interim increase size No significant amount metastatic liver disease , define follow : Lesions occupy 25 % liver image abnormal liver function test abnormal synthetic liver function Performance status Lansky 50100 % ( 10 year age ) Performance status Karnofsky 50100 % ( 10 year age ) Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 ( transfusion independent ) Hemoglobin least 8.0 g/dL ( transfusion allow ) No concurrent CYP3A4 inhibitor , include follow : Grapefruit juice Erythromycin Azithromycin Clarithromycin Rifampin analog Fluconazole Ketoconazole Itraconazole Cimetidine Cannabinoids ( marijuana dronabinol ) Leukotriene inhibitor use asthma ( e.g. , zafirlukast , montelukast , zileuton ) Bilirubin great upper limit normal ( ULN ) Total alkaline phosphatase great ULN Hepatic fraction alkaline phosphatase 5 nucleotidase great ULN SGOT SGPT ≤ 2.5 time ULN Albumin ≥ 2.5 g/dL Gammaglutamyl transferase &lt; 2.5 time ULN Maximum creatinine base age follow : 0.8 mg/dL ( 5 year age ) 1.0 mg/dL ( 6 10 year age ) 1.2 mg/dL ( 11 15 year age ) 1.5 mg/dL ( 15 year age ) Creatinine clearance radioisotope glomerular filtration rate ( GFR ) least 70 mL/min No uncompensated congestive heart failure within past 6 month Not pregnant nursing Fertile patient must use effective contraception 2 month study participation No active uncontrolled infection Weight ≥ 15 kilogram More 1 week since prior growth factor support platelet white blood cell number function At least 7 day since prior biologic agent recover No prior allogeneic stem cell transplantation No concurrent immunomodulating agent More 3 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) recover No 2 prior multiagent chemotherapy regimens No concurrent anticancer chemotherapy Concurrent steroid allow At least 6 week since prior since prior extend radiotherapy recover No prior total body radiotherapy Concurrent radiotherapy localize painful lesion allow provide least 1 measurable lesion irradiated* At least 7 day since prior enzymeinducing anticonvulsant ( e.g. , carbamazepine , phenobarbital , phenytoin ) No concurrent enzymeinducing anticonvulsant No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>